Roundtable Discussion: Perez Explores Therapeutic Options in RET-Mutated NSCLC
August 8th 2021Molecular testing practices and treatment decisions can vary for patients with non–small cell lung cancer. Cesar A. Perez, MD, and a group of other physicians discussed next steps in care for a patient with non–small cell lung cancer whose molecular test results revealed a RET mutation.
Combination of Tafasitamab/Lenalidomide Demonstrates Positive Efficacy in DLBCL
August 6th 2021The laboratory results, lymph node biopsy, imaging studies and other information of a 75-year-old patient with diffuse large B-cell lymphoma were brought into consideration during a Targeted Oncology Case-Based Roundtable discussion around treatment with tafasitamab and lenalidomide (Revlimid).
PARP Inhibitors an Option for Metastatic Castration-Resistant Prostate Cancer
August 5th 2021During a Targeted Oncology Case-Based Roundtable event, Tian Zhang, MD, MHS, an assistant professor of Medicine at Duke Cancer Institute, discusses the case of a 60-year-old patients with metastatic castration-resistant prostate cancer.
The Impact of Immunotherapy Use in Small Cell Lung Cancer
July 31st 2021During a Targeted Oncology Case-Based Roundtable event, Jarushka Naidoo, MB, BCh, MHS. discussed the case of a 73-year-old patient with small cell lung cancer who first presented with shortness of breath, productive cough, chest pain, and fatigue.